These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 29020233)

  • 1. Effectiveness of Intramuscular Immunoglobulin in Unvaccinated Family Members After Household Measles Exposure.
    Salzman MB; Cherry JD
    Clin Infect Dis; 2017 Nov; 65(11):1955-1956. PubMed ID: 29020233
    [No Abstract]   [Full Text] [Related]  

  • 2. Current efficacy of postexposure prophylaxis against measles with immunoglobulin.
    Endo A; Izumi H; Miyashita M; Taniguchi K; Okubo O; Harada K
    J Pediatr; 2001 Jun; 138(6):926-8. PubMed ID: 11391343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The optimal dose of disease-specific antibodies for post-exposure prophylaxis of measles and rubella in Australia: new guidelines recommended.
    Young MK; Ng SK; Nimmo GR; Cripps AW
    Expert Opin Drug Metab Toxicol; 2018 Jul; 14(7):663-669. PubMed ID: 29865869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure of intravenous immunoglobulin to affect the recovery of immune function after measles.
    Shieh CC; Hsieh KH
    Pediatr Infect Dis J; 1989 Dec; 8(12):888-91. PubMed ID: 2626291
    [No Abstract]   [Full Text] [Related]  

  • 5. The effectiveness of prophylaxis for measles contacts in NSW.
    Sheppeard V; Forssman B; Ferson MJ; Moreira C; Campbell-Lloyd S; Dwyer DE; McAnulty JM
    N S W Public Health Bull; 2009; 20(5-6):81-5. PubMed ID: 19552854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimated protective effectiveness of intramuscular immune serum globulin post-exposure prophylaxis during a measles outbreak in British Columbia, Canada, 2014.
    Bigham M; Murti M; Fung C; Hemming F; Loadman S; Stam R; Van Buynder P; Lem M
    Vaccine; 2017 May; 35(20):2723-2727. PubMed ID: 28392140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-exposure prophylaxis for measles with immunoglobulins revised recommendations of the standing committee on vaccination in Germany.
    Matysiak-Klose D; Santibanez S; Schwerdtfeger C; Koch J; von Bernuth H; Hengel H; Littmann M; Terhardt M; Wicker S; Mankertz A; Heininger U
    Vaccine; 2018 Dec; 36(52):7916-7922. PubMed ID: 30478003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measles immunity in Israeli young adults: effects of second immunization at 18 years of age.
    Olsha M; Mendelson E; Shohat T; Cohen D; Duvdevani P; Lerman Y; Danon YL
    Isr J Med Sci; 1994 Aug; 30(8):596-9. PubMed ID: 8045739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Polyvalent immunoglobulins in prevention of viral infections in children with neoplastic diseases treated with immunosuppressive therapy].
    Graf N; Hille A; Jost W; Müller J
    Padiatr Padol; 1991; 26(4):187-91. PubMed ID: 1749627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunity to measles during pregnancy.
    Wallace MR; Hooper DG
    Clin Infect Dis; 1992 Jun; 14(6):1262-3. PubMed ID: 1623085
    [No Abstract]   [Full Text] [Related]  

  • 11. Measles vaccination effectiveness among children under 5 years of age in Kampala, Uganda.
    Mupere E; Karamagi C; Zirembuzi G; Grabowsky M; de Swart RL; Nanyunja M; Mayanja H
    Vaccine; 2006 May; 24(19):4111-5. PubMed ID: 16554111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoglobulin prophylaxis of measles in acute lymphoblastic leukaemia.
    Kay HE; Rankin A
    Lancet; 1984 Apr; 1(8382):901-2. PubMed ID: 6143200
    [No Abstract]   [Full Text] [Related]  

  • 13. Do Australian immunoglobulin products meet international measles antibody titer standards?
    Young MK; Bertolini J; Kotharu P; Maher D; Cripps AW
    Hum Vaccin Immunother; 2017 Mar; 13(3):607-612. PubMed ID: 27763809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of human immunoglobulins in premature infants.
    Stiehm ER
    Am J Pediatr Hematol Oncol; 1989; 11(2):235-7. PubMed ID: 2502038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measles susceptibility in two Pacific atoll populations. Epidemiological factors and response to live attenuated measles virus.
    Willis MF; Warburton MF
    Med J Aust; 1974 May; 1(20):789-93. PubMed ID: 4853112
    [No Abstract]   [Full Text] [Related]  

  • 16. Slow subcutaneous immunoglobulin therapy in a patient with reactions to intramuscular immunoglobulin.
    Welch MJ; Stiehm ER
    J Clin Immunol; 1983 Jul; 3(3):285-6. PubMed ID: 6885970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Appropriate therapeutic use of immunoglobulin.
    Stiehm ER
    Transfus Med Rev; 1996 Jul; 10(3):203-21. PubMed ID: 8809970
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunization against measles in children at risk for severe disease.
    Wesley A; Coovadia HM; Watson AR
    Trans R Soc Trop Med Hyg; 1979; 73(6):710-5. PubMed ID: 120046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of subclinical infection on maintaining immunity against measles in vaccinated children in West Africa.
    Whittle HC; Aaby P; Samb B; Jensen H; Bennett J; Simondon F
    Lancet; 1999 Jan; 353(9147):98-102. PubMed ID: 10023894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody response and clinical reactions in children given measles vaccine with immunoglobulin.
    Lingam S; Miller CL; Clarke M; Pateman J
    Br Med J (Clin Res Ed); 1986 Apr; 292(6527):1044-5. PubMed ID: 3083994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.